Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs
Shares of Biocon Ltd rose 2% to Rs 361.25 on the BSE after its subsidiary, Biocon Biologics, received U.S. FDA approval for two denosumab biosimilars, Bosaya and Aukelso. The regulator also granted provisional interchangeability for both drugs, allowing pharmacy-level substitution, which could (...)
Site référencé: The Economic Times
The Economic Times
Chris Wood of Jefferies has a warning for investors chasing AI stocks
17/09/2025
Sovereign gold bond one of dumbest government borrowing programs in world : Fundoo Professor
17/09/2025
MCX shares soar 5% after Sebi chairman’s comments. Here’s what triggered the move
17/09/2025
NSDL gets ‘Neutral’ rating as Motilal Oswal initiates coverage, sees 8% downside
17/09/2025
Fed may trip the stimulation wire
17/09/2025
Mutual funds and ETFs are for losers, says Rich Dad Poor Dad author Robert Kiyosaki. Here's why
17/09/2025
